The prevalence of short sleep duration increased among working American adults from 2010 to 2018.
Continuous positive airway pressure may be a preferred alternative to noninvasive ventilation as first-line therapy in stable ambulatory patients with obesity hypoventilation syndrome and concurrent severe obstructive sleep apnea.
Wakix is a selective H3 receptor antagonist/inverse agonist and the first treatment for narcolepsy that is not scheduled as a controlled substance.
The FDA has rejected the supplemental New Drug Application for Hetlioz (tasimelteon; Vanda Pharmaceuticals) for the treatment of jet lag disorder.
Continuous positive airway pressure treatment reduces depression symptoms in patients with coexisting obstructive sleep apnea and cardiovascular disease.
In this single-center, prospective, cross-sectional cohort study, the authors aimed to compare the efficacy of zolpidem to melatonin in the treatment of hospital-related insomnia.
The Drug Enforcement Agency (DEA) has designated Sunosi (solriamfetol; Jazz Pharmaceuticals) a Schedule IV controlled substance.
Simple tweaks to eating and sleeping patterns of “night owls” can lead to significant improvements in sleep/wake timing.
Stimulus control and sleep restriction therapy more effective than multiple-component treatments
Smoking may be related to the severity of obstructive sleep apnea.